Grand Pharmaceutical Group (HKG:0512) sold about 45.2% of its stake in Telix Pharmaceuticals (ASX:TLX) for AU$143 million in an off-the-market transaction, a Friday Hong Kong bourse filing said.
The group will use proceeds from the disposal to fund its clinical development plans in areas of unmet need, including projects under its partnership with Telix.
Grand Pharmaceutical Group plans not to sell the remaining stake it holds in Telix in the coming 12 months.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.